Cantor Fitzgerald Weighs in on SI-BONE, Inc.’s FY2022 Earnings (NASDAQ:SIBN)

SI-BONE, Inc. (NASDAQ:SIBNGet Rating) – Analysts at Cantor Fitzgerald issued their FY2022 earnings estimates for shares of SI-BONE in a report issued on Wednesday, November 16th. Cantor Fitzgerald analyst R. Osborn expects that the company will earn ($1.86) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for SI-BONE’s current full-year earnings is ($1.87) per share. Cantor Fitzgerald also issued estimates for SI-BONE’s FY2023 earnings at ($1.26) EPS.

A number of other brokerages have also recently weighed in on SIBN. JMP Securities decreased their price target on shares of SI-BONE from $36.00 to $32.00 and set a “market outperform” rating for the company in a research note on Tuesday, November 8th. Morgan Stanley cut their price objective on shares of SI-BONE to $21.00 in a research report on Tuesday. Jefferies Financial Group began coverage on shares of SI-BONE in a report on Wednesday, October 12th. They issued a “buy” rating and a $20.00 price target for the company. Needham & Company LLC cut their price target on shares of SI-BONE from $24.00 to $22.00 and set a “buy” rating for the company in a report on Tuesday, November 8th. Finally, Truist Financial dropped their target price on shares of SI-BONE to $17.00 in a report on Friday, July 22nd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $25.88.

SI-BONE Stock Down 3.3 %

Shares of NASDAQ:SIBN opened at $12.17 on Friday. The stock has a market cap of $419.82 million, a P/E ratio of -6.41 and a beta of 1.13. The firm has a fifty day moving average price of $16.81 and a 200 day moving average price of $15.58. The company has a debt-to-equity ratio of 0.33, a current ratio of 7.50 and a quick ratio of 6.59. SI-BONE has a 1-year low of $11.22 and a 1-year high of $23.71.

Insider Activity

In related news, Director Jeffrey W. Dunn sold 7,969 shares of SI-BONE stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $13.17, for a total value of $104,951.73. Following the completion of the sale, the director now owns 103,731 shares in the company, valued at $1,366,137.27. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Jeffrey W. Dunn sold 7,969 shares of SI-BONE stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $13.17, for a total value of $104,951.73. Following the completion of the sale, the director now owns 103,731 shares in the company, valued at $1,366,137.27. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Michael A. Pisetsky sold 3,477 shares of SI-BONE stock in a transaction on Wednesday, November 16th. The stock was sold at an average price of $13.17, for a total transaction of $45,792.09. Following the completion of the sale, the senior vice president now owns 116,062 shares of the company’s stock, valued at approximately $1,528,536.54. The disclosure for this sale can be found here. Insiders have sold 19,966 shares of company stock worth $278,984 over the last 90 days. Company insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On SI-BONE

A number of hedge funds have recently added to or reduced their stakes in the business. Brown Advisory Inc. boosted its holdings in SI-BONE by 0.8% in the third quarter. Brown Advisory Inc. now owns 3,732,106 shares of the company’s stock worth $65,163,000 after purchasing an additional 30,308 shares during the period. BlackRock Inc. boosted its holdings in shares of SI-BONE by 0.4% during the first quarter. BlackRock Inc. now owns 2,709,443 shares of the company’s stock valued at $61,233,000 after acquiring an additional 9,645 shares during the period. First Light Asset Management LLC boosted its holdings in shares of SI-BONE by 1.1% during the third quarter. First Light Asset Management LLC now owns 2,027,963 shares of the company’s stock valued at $35,408,000 after acquiring an additional 21,659 shares during the period. Vanguard Group Inc. boosted its holdings in shares of SI-BONE by 1.3% during the third quarter. Vanguard Group Inc. now owns 1,606,903 shares of the company’s stock valued at $28,056,000 after acquiring an additional 20,117 shares during the period. Finally, Point72 Asset Management L.P. boosted its holdings in shares of SI-BONE by 17.5% during the third quarter. Point72 Asset Management L.P. now owns 1,303,904 shares of the company’s stock valued at $22,766,000 after acquiring an additional 193,941 shares during the period.

SI-BONE Company Profile

(Get Rating)

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures.

Featured Stories

Earnings History and Estimates for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.